<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332848</url>
  </required_header>
  <id_info>
    <org_study_id>202001085MINB</org_study_id>
    <nct_id>NCT04332848</nct_id>
  </id_info>
  <brief_title>Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection</brief_title>
  <official_title>Comparison of Susceptibility Testing Guided Versus Empirical Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: Therefore, we aimed to&#xD;
&#xD;
        1. compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in&#xD;
           the third-line eradication for refractory H. pylori infection&#xD;
&#xD;
        2. assess the long-term impact of eradication therapy on the antibiotic resistance and&#xD;
           microbiota of the gut flora and the metabolic factors.&#xD;
&#xD;
      Methods: This will be a multi-center, open labeled trial&#xD;
&#xD;
      Patients: 360 patients with failure to H. pylori eradication for at least two times will be&#xD;
      enrolled Determination of antibiotic resistance of H. pylori:&#xD;
&#xD;
      Agar dilution test will be used to determine the minimum inhibitory concentrations of&#xD;
      levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of&#xD;
      antibiotics.&#xD;
&#xD;
      Treatment regimens and assignment: Eligible patients will be randomized to receive either one&#xD;
      of the treatments (A) Susceptibility testing guided therapy or (B) Empirical therapy&#xD;
&#xD;
      Outcome Measurement:&#xD;
&#xD;
      Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT)&#xD;
      analyses.&#xD;
&#xD;
      Secondary End Point: 1. Eradication rate according to per protocol analysis (PP analysis); 2.&#xD;
      Frequency of adverse effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the eradication rate in the third treatment according to intention-to treat (ITT) analysis.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Eradication rate will be determined by urea breath test at least 6 weeks after completion of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>2 weeks</time_frame>
    <description>A standard interview and questionaire will be used to assess the adverse effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>(B) Empirical therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>choose antibiotics according to drug history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(A) Susceptibility testing guided therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>choose antibiotics according to susceptibility testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ET</intervention_name>
    <description>Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy</description>
    <arm_group_label>(B) Empirical therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGT</intervention_name>
    <description>Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy</description>
    <arm_group_label>(A) Susceptibility testing guided therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Adult (equal or greater than 20 years old) patients who failed from at least two&#xD;
             eradication therapies for H. pylori infection will be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mei-Jyh Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mei-Jyh Chen</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>66280</phone_ext>
    <email>migichen@ntuh.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu-Chun Huang</last_name>
    <email>nneder34@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Jyh Chen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori,Susceptibility testing,empirical,third-line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

